While current treatment approaches mostly target cancer as a homogeneous disease (e.g., ER antagonists used to treat ER+ breast cancers), intratumour heterogeneity often contributes to the acquisition of therapy resistance through the expansion of pre‐existing resistant cells.12 This evidence concerns the gene ESR1 and breast carcinoma.